Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Ahmedabad-based pharmaceutical company (formerly Cadila Healthcare) with a large US generics business (including complex generics and injectables), Indian branded formulations, biosimilars, vaccines (developed ZyCoV-D COVID DNA vaccine) and consumer wellness via listed subsidiary Zydus Wellness. Pipeline includes NCEs such as saroglitazar (Lipaglyn) and rare-disease/speciality bets in the US. Revenue is driven by US generic launches/exclusivities and Indian chronic-therapy brands.
A top-five Indian pharma company by revenue and among the largest Indian generic suppliers to the US.
Zydus Lifesciences Ltd. is a constituent of NIFTY 100, NIFTY 200, NIFTY 500, NIFTY HEALTHCARE, NIFTY NEXT 50, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Zydus Lifesciences Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 50.09 | 44.97 | 38.14 |
| Book value / share (₹) | 294.06 | 262.01 | 219.70 |
| Return on equity | 17.0% | 0.6% | 0.5% |
| Return on capital employed | 19.3% | 21.8% | 19.3% |
| Operating margin | 26.0% | 26.4% | 23.6% |
| Net margin | 18.9% | 20.1% | 20.3% |
| EBITDA | ₹8,475 Cr | ₹7,059 Cr | ₹5,384 Cr |
| Free cash flow | ₹-1,277 Cr | ₹5,064 Cr | ₹2,321 Cr |
| Total debt | ₹11,770 Cr | ₹3,170 Cr | ₹769 Cr |
| Debt to equity | 0.40 | 0.12 | 0.03 |
| Interest coverage | 16.1 | 37.0 | 56.9 |
| Current ratio | 1.27 | 1.89 | 2.14 |
| Shares outstanding | 1,00,60,00,000 | 1,00,60,00,000 | 1,00,60,00,000 |
Open the full income statement, balance sheet and cash flow for ZYDUSLIFE →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.